Loading...
PLENARY SESSION
PLENARY SESSION

24 November 2017

09:00 - 10:30

PLENARY SESSION

  9:00 - 10:30
  Room: Flores

The ‘dream team’ can make it happen – great science, business sense and committed funders

Co-inventor of the GS100 technology, Alessandro Sannino, is also Professor of Polymer Science and Technology, and Director of the Bioslabs at the University of Salento.

In this session he will share his experiences of setting up and developing his own company, talking about what went well, and what did not – and how we can better support spin-offs. Gelesis has been successful in developing early stage technology from conception to clinical trials with patients. The challenges facing biotech spin-offs are daunting. Listening to the progress of this technology to assist the treatment of diabetes sufferers, gives us all an opportunity to remain hopeful that the triumvirate of great science, hungry entrepreneurs and VC investment can benefit patients.

Listening to the progress of this technology to assist the treatment of diabetes and obesity, gives us all an opportunity to remain hopeful that the triumvirate of great science, hungry entrepreneurs and VC investment can benefit patients.

Keynote speaker: Alessandro Sannino, Chief Project Scientist, Gelesis, Italy

Moderator: Henric Rhedin, President, ASTP-Proton